MRKR
MRKR
NASDAQ · Biotechnology

Marker Therapeutics Inc

$1.32
+0.02 (+1.54%)
Financial Highlights (FY 2026)
Revenue
12.81M
Net Income
-20,851,101
Gross Margin
Profit Margin
-162.8%
Rev Growth
+74.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 65.0% 65.0%
Operating Margin -168.7% -151.8% -4.2% -4.2%
Profit Margin -162.8% -154.7% -4.0% -4.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 12.81M 7.34M 3.86M 4.10M
Gross Profit 2.51M 2.67M
Operating Income -21,604,612 -11,141,502 -161,214 -174,270
Net Income -20,851,101 -10,752,917 -155,305 -171,738
Gross Margin 65.0% 65.0%
Operating Margin -168.7% -151.8% -4.2% -4.2%
Profit Margin -162.8% -154.7% -4.0% -4.2%
Rev Growth +74.5% +74.5% +19.6% -4.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 9.32M 9.35M
Total Equity 11.45M 10.87M
D/E Ratio 0.81 0.86
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -21,603,136 -11,759,671 -205,551 -243,961
Free Cash Flow -168,121 -167,490